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Abstract: Risk assessment during clinical product development needs to be conducted in a 
thorough and rigorous manner. However, it is impossible to identify all safety concerns during 
controlled clinical trials. Once a product is marketed, there is generally a large increase in the 
number of patients exposed, including those with comorbid conditions and those being treated 
with concomitant medications. Therefore, postmarketing safety data collection and clinical 
risk assessment based on observational data are critical for evaluating and characterizing a 
product’s risk profile and for making informed decisions on risk minimization. Information 
science promises to deliver effective e-clinical or e-health solutions to realize several core 
benefits: time savings, high quality, cost reductions, and increased efficiencies with safer and 
more efficacious medicines. The development and use of standard-based pharmacovigilance 
system with integration connection to electronic medical records, electronic health records, 
and clinical data management system holds promise as a tool for enabling early drug safety 
detections, data mining, results interpretation, assisting in safety decision making, and clinical 
collaborations among clinical partners or different functional groups. The availability of a publicly 
accessible global safety database updated on a frequent basis would further enhance detection 
and communication about safety issues. Due to recent high-profile drug safety problems, the 
pharmaceutical industry is faced with greater regulatory enforcement and increased account-
ability demands for the protection and welfare of patients. This changing climate requires 
biopharmaceutical companies to take a more proactive approach in dealing with drug safety 
and pharmacovigilance.
Keywords: information technology, pharmacovigilance, safety, standard, risk management, 
adverse event, adverse drug reaction
Introduction
It is recognized that information technology (IT) has entered and transformed the 
world of health care and clinical medicine in which the work of doctors and the care 
of patients proceed with higher quality, efficiency and lower cost. It is also no secret 
that IT has merged into clinical safety practice and sparks the creation of worldwide 
pharmacovigilance systems for safety signal detection. The IT transformative force 
and health IT adoption have fundamentally changed the conduct of clinical research, 
practice of medicine, and medicinal safety monitoring.
In the wake of recent drug withdrawals, to regain the trust of patients, health care 
providers and regulators demand that biopharmaceutical or medical device firms show 
a demonstrated commitment to safety that goes beyond mere compliance. In today’s 
world, pharmacovigilance pushes new boundaries and it is no longer sufficient Drug, Healthcare and Patient Safety 2009:1 36
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to simply report adverse events along with efficacy and 
quality requirements. Regulators are demanding proactive 
surveillance programs that include comprehensive risk 
management plans and signal detection/analysis throughout 
a clinical product’s lifecycle. Organizations that take the lead 
in developing a more proactive and long-term approach to 
manage the safety of their products recognize that success 
requires a continuous, consistent process from preclinical 
research onward. This is achieved through developing a 
good clinical safety practice that shows the company was 
aware of and acted on every safety issue as it developed for 
a product or device. In this review, we seek to clarify some 
of the issues that are central to current discussions about 
pharmacovigilance, focusing on topics critical to biophar-
maceutical or medical device companies with marketed 
products in human use. This paper is prepared from industry 
perspectives to present and analyze benefits, advantages, 
challenges and risks associated with pharmacovigilance 
based on systematic overview. This article addresses four 
questions: What exactly is pharmacovigilance? What do we 
know of its benefits and risks? What challenges are out there 
preventing its widespread usage? And what does the future 
hold for pharmacovigilance in worldwide medicine?
It is now generally accepted that part of the process of 
evaluating drug safety needs to happen in the postmarketing 
phase though judgment as to whether and how this might 
happen lies with the regulators. The stronger the national 
systems of pharmacovigilance and adverse drug reaction 
(ADR) reporting, the more likely reasonable regulatory 
decisions will be made for the early release of new drugs with 
the promise of therapeutic advances. Legislation governing 
the regulatory process in most countries allows for condi-
tions to be placed on approvals, such as a requirement that 
there should be detailed pharmacovigilance in the early 
years after a drug’s release. Careful safety monitoring is not 
restricted, however, to new drugs or to significant therapeutic 
advances. It has a critical role to play in the introduction 
of generic medicines, and in review of the safety profile of 
older medicines already available as well, where new safety 
issues may have arisen. While spontaneous reporting remains 
a cornerstone of pharmacovigilance in the regulatory envi-
ronment, and is indispensable for signal detection, the need 
for more active surveillance has also become increasingly 
clear. Without information on utilization and on the extent of 
consumption, spontaneous reports are unable to determine the 
frequency of an ADR attributable to a product, or its safety in 
relation to a comparator.1 More systematic and robust epide-
miological methods that take into account the limitations of 
spontaneous reporting or postmarketing studies are required 
to address these key safety questions. They need to be incor-
porated into postmarketing surveillance programs.
What is pharmacovigilance?
Pharmacovigilance is a branch of pharmacological science 
encompassing all scientific and data gathering activities 
relating to the detection, assessment, understanding and 
prevention of adverse events of medicines and medical 
devices.1 This includes the use of pharmacoepidemiologic 
studies. These activities are undertaken with the goal of 
identifying adverse events and understanding, to the extent 
possible, their nature, frequency, and potential risk factors. 
Pharmacovigilance in principle involves the identification and 
evaluation of safety signals. Safety signal refers to a concern 
about an excess of adverse events compared to what would 
be expected to be associated with a product’s use. Signals 
can arise from postmarketing data and other sources, such 
as preclinical data and events associated with other products 
in the same pharmacologic class. It is possible that even a 
single well documented case report can be viewed as a signal, 
particularly if the report describes a positive rechallenge or if 
the event is extremely rare in the absence of drug use. Signals 
generally indicate the need for further investigation, which 
may or may not lead to the conclusion that the product caused 
the event. After a signal is identified, it should be further 
assessed to determine whether it represents a potential safety 
risk and whether other action should be taken.2 Pharmacovigi-
lance is particularly concerned with adverse drug reactions, or 
ADRs, which are defined as: “A response to a drug which is 
noxious and unintended, and which occurs at doses normally 
used… for the prophylaxis, diagnosis or therapy of disease, or 
for the modification of physiological function.”3 Many other 
issues are also relevant to pharmacovigilance science:1
•	 Substandard medicines
•	 Medication errors
•	 Lack of efficacy reports
•	 Use of medicines for indications that are not approved 
and for which there is inadequate scientific basis
•	 Case reports of acute and chronic poisoning
•	 Assessment of drug-related mortality
•	 Abuse and misuse of medicines
•	 Adverse interactions of medicines with chemicals, other 
medicines, and food
The specific aims of pharmacovigilance are to:1
•	 Improve patient care and safety in relation to the 
use of medicines and all medical and paramedical 
interventionsDrug, Healthcare and Patient Safety 2009:1 37
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•	 Improve public health and safety in relation to the use of 
medicines
•	 Contribute to the assessment of benefit, harm, effec-
tiveness and risk of medicines, encouraging their 
safe, rational and more effective (including cost-
effective) use
•	 Promote understanding, education and clinical training 
in pharmacovigilance and its effective communication to 
the public.
Pharmacovigilance has developed and will continue to 
develop in response to the special needs and according to 
the particular strengths of members of the WHO program 
and beyond. Such active influence needs to be encouraged 
and fostered; it is a source of vigor and originality that has 
contributed much to international practice and standards. Phar-
macovigilance is gaining traction among doctors and scientists 
as the number of stories of drug recalls increases in the global 
mass media. Because clinical trials involve several thousand 
patients at most, less common side effects and ADRs are often 
unknown at the time a drug enters the market. Even very severe 
ADRs, such as liver damage, are often undetected because study 
populations are small. Postmarketing pharmacovigilance uses 
tools such as data mining and electronic case report forms to 
identify the relationships between drugs and ADRs. In brief, 
an electronic data capture (EDC) system is a computerized 
system designed for automated support of clinical data collec-
tion, reporting, query resolution, randomization, and validation, 
among other features, in conducting clinical trials. Though EDC 
technologies offer superior advantages over traditional paper-
based systems, collecting, monitoring, coding, reconciling, and 
analyzing safety data can be challenging.4 To realize the full 
potential of the information revolution in e-clinical research 
as compared with traditional paper-based studies, both spon-
sor and site users will probably have to change the way their 
offices and days are organized, how they enter and retrieve 
patient information, how data is entered, the process by which 
they issue, answer, or close queries, and the ways in which they 
relate to colleagues and clinical research organizations (CROs) 
and interact with their patients. Safety scientists will have to 
find ways to understand and analyze huge amounts of safety 
information across different studies or systems and coordinate 
with third party independent committees to enter adjudication 
results. In other words, effective use of e-technologies depends 
as much on managing change as it does on information manage-
ment, and change has never been easy for sponsor e-clinical 
system implementation and integration.
The capacity of IT staff to realize this transformational 
vision will also depend on something else: whether the 
e-systems introduced are designed or configured to capture 
the protocol required or compliance necessitated informa-
tion such as unanticipated ADRs (UADRs). It is one thing to 
digitize the current case report form so that the information 
sponsors now require is available to them electronically. 
It is another thing to make certain that all the data needed 
for pharmacovigilance purposes are collected, coded 
properly, and data are accessible for functional group review 
and reconcile with in-house product performance system, 
organized, apply decision algorithms, and provide the result 
to management and regulatory agencies when and where 
they need it. The EDC technology products now being sold 
are intended to meet the present needs of both sponsor and 
site users with certain vendor-based differential functions – as 
would any product be that is aimed at attracting consumers in 
a well-functioning market. Indeed, our experience indicates 
that understanding limitations and opportunities offered by 
EDC vendor, configuring EDC system to meet data capturing 
needs based on sponsor IT or data management profile, and 
collaborating with vendor to offer flexible configurations, are 
key to EDC implementation success.5 Technology innovators 
and EDC vendors, however, imagine a world in which elec-
tronic system meets needs that most sponsor and site users do 
not think they have. How to meet future needs, how to integrate 
EDC clinical trial data with eHR, and how to persuade EDC 
vendors to invest in such innovative systems, is something 
involving collaborative efforts from many players.
Benefits and risks of 
pharmacovigilance technologies
The idea that randomized clinical trials can establish 
product safety and effectiveness is a core principle of the 
pharmaceutical industry. Neither the clinical trials process 
nor the approval procedures of the US Food and Drug 
Administration (FDA) provide a perfect guarantee of safety 
for all potential consumers under all circumstances. Despite 
this fact, there are viable pharmacovigilance technology 
solutions that biopharmaceutical companies can implement 
to systematically detect, assess, understand, and prevent 
adverse drug reactions. When built into clinical research 
and development practices, pharmacovigilance technologies 
assist biopharmaceutical firms in enhancing patient safety 
while reducing or even preventing costly safety-related 
withdrawals. It is recognized that clinical data mining 
and signal detection associated with pharmacovigilance 
technology contribute to potential benefits in providing:6
•	 Systematic, automated and practical means of screening 
large datasetsDrug, Healthcare and Patient Safety 2009:1 38
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•	 Better utilization of the large safety databases maintained 
by the FDA, the World Health Organization (WHO) and 
other organizations
•	 Improved efficiency by focusing pharmacovigilance 
efforts on key reporting associations
•	 Positive contributions to public health by identifying 
potential safety issues more quickly and/or more 
accurately than traditional pharmacovigilance methods
•	 Better decision support for the pharmaceutical industry 
and regulators
•	 Potential to clarify the many complex interdependent 
factors (eg, concomitant drugs and/or diseases) that can 
play a role in the development of adverse events in a 
clinical setting
•	 Value by detecting disproportionalities involving multiple 
drugs or multiple events that would be too difficult to 
detect by traditional methods.
Adopting good pharmacovigilance practice in clinical 
safety monitoring and analysis and having an aptitude to 
utilize the advantages pharmacovigilance technology solutions 
provide are key to unlock the power of pharmacovigilance and 
maximize clinical safety returns in an evolving drug safety 
environment. One needs to realize that pharmacovigilance is 
a tool and should be applied into clinical context to achieve its 
intended functions. One critical component of good pharma-
covigilance practice is centered on acquiring complete quality 
data from reported source on adverse events. Spontaneous 
case reports of adverse events submitted to the sponsor and 
FDA, and reports from other sources, such as the medical 
literature or clinical studies, may generate signals of adverse 
effects of drugs. The quality of the reports is critical for 
appropriate evaluation of the relationship between the product 
and adverse events.2 Table 1 summarizes necessary good 
case report data elements, what to be included for reporting 
Table 1 Good case report characteristics and summarized descriptive analysis points of a case series
Clinical data elements Medication error Causal relationship features Critical analysis – case series
AE description or disease 
experience, including time to 
onset of signs or symptoms
Products involved Occurrence of the adverse event 
in the expected time
The clinical and laboratory 
manifestations and course of 
the event
Suspected and concomitant 
MEDS details (dose, lot number, 
schedule, dates, duration)
Sequence of events leading up 
to the error
Absence of symptoms related to 
the event prior to exposure
Demographic characteristics of 
patients with events (age, gender, 
race)
Documentation of AE diagnosis, 
including methods used to 
make the diagnosis
Work environment in which 
the error occurred
Evidence of positive dechallenge 
or positive rechallenge
Exposure duration
Clinical course of the event 
and patient outcomes 
(eg, hospitalization or death)
Types of personnel involved 
with the error, type(s) of error, 
and contributing factors
Consistency of the event with 
the established pharmacological/
toxicological effects of the 
product
Time from initiation of product 
exposure to the adverse event;
Relevant therapeutic measures 
and laboratory data at baseline, 
during therapy, and subsequent 
to therapy
Patient outcomes may not be 
available at initial reporting. F/U 
reports can convey important 
information about the course of 
the event and serious outcomes, 
such as hospitalization or death
Consistency of the event with 
the known effects of other 
products in the class
Doses used in cases, including 
labeled doses, greater than 
labeled doses, and overdoses;
Information about response to 
dechallenge and rechallenge
All appropriate information 
outlined in NCC MERP
Other supporting evidence from 
preclinical, clinical, and/or phar-
macoepidemiologic studies
Use of concomitant medications
Any other relevant information Absence of alternative explana-
tions for the event
Presence of co-morbid conditions
Route of administration
Lot numbers, if available, for 
products used in patients with AE
Changes in event reporting rate 
over calendar time or product 
life cycle
Abbreviations:   AE, adverse event; MEDS, medications; NCC MERP, National Coordinating Council for Medication Error Reporting and Prevention; F/U, Follow-up.Drug, Healthcare and Patient Safety 2009:1 39
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medication errors for recommended good case reports, key 
features that may suggest a causal relationship between the 
use of a product and the adverse event, and critical analysis 
points that characterize and identify risk factors.
Good pharmacovigilance processes (GPVP) focus on the 
enhancement of the reports that are most likely to be important. 
In parallel to any regulatory reporting (submission) triage, 
these reports need to have both their potential maximized 
and the value measured. That measurement must be both 
as an individual and in a case-series. The goal of GPVP 
is to clearly and accurately identify rare, serious, unusual 
or unexpected adverse drug reactions such as UADEs as 
soon as possible after product market launch. Therefore, 
GPVP in the 21st century is best practices-driven with IT 
systems-enabling support. Modern internet and communi-
cation technologies have allowed these best practices to be 
joined in a supportable process. They support the ‘clinical 
art’ of pharmacovigilance by providing service-oriented 
architecture, powerful data-mining and query tools, and 
work environments for case-series management and product 
preparation. Pharmacovigilance technology systems can be 
effective in detecting what may be otherwise invisible to the 
human eye, increasing productivity and are less likely to miss 
important public health information hidden in “haystacks” of 
data.7 It is demonstrated that full product safety assessment 
can be conducted by such technologies in an efficient and 
effective manner (Figure 1).
Spontaneous reporting is the core data-generating system 
of international pharmacovigilance, relying on health care 
professionals (and in some places consumers) to identify and 
report any suspected ADR to their national pharmacovigilance 
center or to the manufacturer.8 Spontaneous reports are almost 
always submitted voluntarily. One of this system’s major 
weaknesses is under-reporting, a major potential risk area 
in data mining inherent to postmarketing safety databases 
that no signal detection method is likely to overcome. There 
are published examples of known safety issues that are not 
retrospectively identified by data-mining methods using pre-
defined thresholds.6 Another problem is that overworked medi-
cal personnel do not always see reporting as a priority. If the 
Figure 1 The good pharmacovigilance processes and workflow in a typical sponsor biopharmaceutical firm supported by information technology.  Modern internet and 
communication technologies have enabled improved clinical safety monitoring in a significant way despite anticipated ongoing challenges.
Abbreviations:  ADR, adverse drug reaction; DB, database; PV, pharmacovigilance; CRO, clinical research organization.Drug, Healthcare and Patient Safety 2009:1 40
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symptoms are not serious, they may not notice them at all. 
Even if the symptoms are serious, they may not be recognized 
as the effect of a particular drug. Even so, spontaneous reports 
are a crucial element in the worldwide enterprise of pharma-
covigilance and form the core of the WHO database, which 
includes around 4.6 million reports (as of January 2009),9 
growing annually by about 250,000.10 There are concerns that, 
in some situations, data mining may generate more signals 
than can be followed up effectively with available resources. 
In this case, focus might be directed to signals with the 
greatest public health impact and seriousness. There is also 
concern about the lack of systematic, objective validation of 
the methods, a problem that also exists for traditional pharma-
covigilance methods. Unfortunately, efforts to validate data-
mining methods (and traditional methods) are complicated 
by the absence of a gold standard for identifying true drug 
toxicities, although various imperfect reference standards may 
be used to obtain useful insights on the performance of any 
method. It is not practical to evaluate data-mining methods 
or traditional methods using performance criteria generally 
accepted for screening and diagnostic tests.6 The final risk 
factor worth noting is that pharmacovigilance systems may 
generate errant signals that turn out to be false alarms. This 
can occur because other factors, not adequately adjusted for, 
confound the apparent relationship. Physicians generally 
select treatments on the basis of the subtleties of a patient’s 
clinical status, as well as their own practice preferences. 
As automated algorithms search for associations between 
medication use and adverse events in large observational 
data sets, rigorous analytic techniques will be necessary to 
ensure that confounding does not produce spurious associa-
tions that could generate safety signals warning of nonexistent 
hazards. Or, equally problematic, inadequate analysis could 
conceal a true risk signal that might have been evident with 
more careful adjustment. Simplistic data mining yielding 
inadequately adjusted drug–event associations could thus 
be counterproductive even for first-step signal-generation 
analysis. Fortunately, more sophisticated approaches are 
available to mitigate these risk-assessment risks. Partially 
automated processes based on epidemiologic principles can 
be used to derive relevant covariate information from large, 
comprehensive data sets and use them for advanced multivari-
able adjustment procedures.11
Challenges of pharmacovigilance
There are well-known inherent issues in systematically 
analyzing and interpreting voluntarily submitted data 
involving multiple drugs, medical conditions, and events 
per report, without the benefit of a research protocol, 
randomization, and a control group of persons taking 
the placebo. Other difficulties include chronic under-reporting, 
occasional publicity-driven and litigation-driven episodes of 
over-reporting and misreporting, incomplete and missing 
information, and inconsistencies and changes over time in 
reporting and naming/coding practices.7 In addition, there is 
considerable uncertainty regarding the quality and complete-
ness of the information contained in each data field, including 
dosage, formulation type, timing of exposure, and length of 
exposure and follow-up and in estimating the corresponding 
product exposure and background rate of adverse events. The 
extraction of useful information from this database presents 
multiple challenges, including managing, storing, querying, 
and analyzing such a large amount of data, and resolving 
event and drug dictionary problems and data miscoding. 
There is a need for analytical methods that are capable of 
systematically screening this database to identify potential 
serious adverse events of concern in such a noisy background 
that properly balance the concerns for excessive signaling 
and accounting for background noise.
Another challenge will be determining rules to trigger an 
alert, when to consider a signal likely enough to be real to 
warrant follow-up, and when a signal needs to be elevated to 
represent a potential safety risk.12 If data mining analysis was 
performed on data for millions of people taking thousands 
of drugs, statistic significance could emerge as data on a 
drug–event relationship accumulate, even after adjustment 
for repeated testing. Such P value-driven thresholds could 
result from the size of the population and the strength of the 
supposed association. Taking account of multiple covariates 
such as severity of adverse events, whether a safe alternative 
treatment is available, or how much benefit the drug provides 
will likely cut down the list to prioritize focused follow-up. 
Sundström and Hallberg applied Bayesian confidence propa-
gation neural network (BCPNN) methodology to calculate the 
information component (IC) value for drug-event combina-
tions for drugs belonging to the anatomic therapeutic chemical 
(ATC) classes of the cardiovascular system, musculoskeletal 
system, and nervous system (number of reports = 51,270) 
where only the suspected drug was considered, and also 
where both concomitant and suspected drugs were considered 
using data from the Swedish Drug Information System and 
reported that the proportion of “type C” reactions signaled 
when considering both concomitant and suspected drugs as 
compared with suspected drugs only.13 Conversely, taking 
action prematurely on the basis of inadequate data could 
result in unnecessary confusion and harmful discontinuations Drug, Healthcare and Patient Safety 2009:1 41
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of useful treatments. We cannot know now what inputs will 
be optimal for each decision analysis. But stating such inputs 
transparently up front will help to clarify the decision-making 
process of regulators who will have to act on these signals. 
It will also facilitate the communication of decisions, by 
enabling regulators to frame recommendations or actions in 
terms of prestated assumptions about acceptable risks for a 
given product. If such tools are applied well, the system will 
be able to provide early notice of adverse drug effects that have 
previously taken years to discover. It seems that there is a fine 
balance of judgment on public warnings on possible hazards. 
Caution needs to be exercised to issue public announcement 
on unreal hazards. An excessively high threshold for warnings 
would keep real risks hidden too long, but an excessively low 
threshold could undermine public trust in clinical products, 
the surveillance system, and the entire medical world. Proper 
implementation of the pharmacovigilance technology solu-
tion will require expertise in intelligibly communicating 
information about risks in relation to benefits to clinicians 
and patients alike.
Challenge area also lies in clinical process re-engineering 
to ensure modern pharmacovigilance technology systems 
are configured, tailored, and implemented in the context of 
addressing safety process improvements and organizational 
needs to support daily clinical safety operations. In the past 
four decades from the thalidomide tragedy to the recent 
drug recalls, companies have used pharmacovigilance 
methods to identify rare, easily identified safety problems. 
During the same four decades, we have seen the growth of a 
fragmented clinical or healt hcare system that lacks a unifying 
infrastructure. As a result, this system operates primarily in 
reaction to rather than in anticipation of major pharmaceutical 
safety events. As drug consumption has increased and the 
public has grown to expect greater drug safety, the traditional 
reactive approach has proven largely incapable of addressing 
both shifts in public expectations and regulatory and media 
scrutiny. This reality has revealed improvement areas involved 
in patient safety operations: organizational alignment, opera-
tions management, data management, and risk management. 
Table 2 summarizes key functional activities and recom-
mended best practices under the specified four areas to enable 
realization of the capability of pharmacovigilance systems in 
an adaptive operations framework.
Last but not least, standard-based systems integration 
will present challenges. In sponsor corporate environment, 
pharmacovigilance technology system needs to establish 
interoperable channels with other numerous systems: 
Clinical data management system (CDMS), clinical trial 
management system, product performance system, clinical 
coding application, and potential CRO systems. It seems 
that standardization on signal definitions, common medical 
domains, clinical data elements, case report forms, adverse 
events, and medication coding are critical to ensure quality 
signal analysis. Standardization is also key to ensure success 
of pooled data analysis among all subjects in the pharma-
covigilance databases used. Standardization is challenging 
because we do not have a standard framework yet to allow 
full system integration. Though industry seems to agree that 
XML is the default file format for interchange and messaging, 
there are many implementation details to be defined and 
agreed to enable, for instance, a sponsor postmarketing study 
to talk directly with a hospital electronic health care system. 
It is due to this same systems interoperability challenge that 
current sponsor clinical studies need to collect clinical data in 
a separate EDC or via paper-based case report forms though 
convergence is expected to continue until electronic medical 
or electronic health records become more pervasive within the 
broader health care system. At that point, the ideal solution 
would be to extract patient data directly from the electronic 
medical records as opposed to collecting the data in a separate 
data collection instrument or enable bidirectional channels 
between electronic medical records and CDMS. Collabora-
tion has begun in several initiatives between Clinical Data 
Interchange Standards Consortium (CDISC), HL7, National 
Cancer Institute (NCI), and FDA to encourage adoption of its 
global standards for clinical research, which should continue 
to be harmonized with health care standards, to provide a 
means for interoperability among health care and research 
systems such that clinical research can support informed 
health care decisions and improve patient safety.14,15
The future of pharmacovigilance 
technology
The challenges to manage drug safety efficiently and 
to adhere to regulatory requirements create the strong 
impression that widespread adoption of pharmacovigilance 
is inevitable. As an instrument of reform, pharmacovigilance 
has attributes that ensure its attractiveness to many groups in 
a politically and economically divided health care system that 
is struggling with seemingly insurmountable problems of cost 
and quality and postmarketing clinical studies as well.
Regulatory bodies such as FDA and European Medicines 
Agency (EMEA) are intensifying safety regulations, therefore 
boosting the adoption rates of pharmacovigilance systems by 
biopharmaceutical firms.16 However, the apparent certainty 
of pharmacovigilance adoption needs to be constantly Drug, Healthcare and Patient Safety 2009:1 42
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reexamined due to considerations of a number of challenging 
issues. One is whether the current standardization initiatives 
in reaching interoperability between differential clinical or 
e-health systems among several standard consortiums such as 
CDISC, HL7, NCI, and FDA will have any effect on pharma-
covigilance. If so, to what extent such implementation level 
standard may bring changes and affect ongoing pharmaco-
vigilance monitoring activities? On the technical architecture 
perspective, will modern pharmacovigilance technology 
system offer multi-tier web based application framework so 
that even a new clinical standard definition causes minimum 
modification behind the scene? This certainly presents a 
challenge call to pharmacovigilance technology vendors to 
partner with pharmaceutical firms and health care providers 
to offer flexible, configurable, scalable, and interoperable 
pharmacovigilance technology solutions to meet the future 
pharmacovigilance needs in:1 a) increasing globalization; 
b) web-based sales and information; c) broader safety 
concerns linked to the patterns of drug use within society; 
d) collaborative working approach among biopharmaceutical 
firms, health providers, regulatory agencies, insurance payers, 
CROs, standards consortiums, and central laboratories.
A second debatable question is whether, if the apparent 
automation of technical edit checks of pharmacovigilance 
offers systematic assurance, their definition, range, thresh-
old determination, or data-mining statistical methodology 
associated with alert or signal triggering requires some 
level of standardizations to enable consolidated efforts, 
comparability, and interoperability. If so, achieving this goal 
requires multiple stakeholders’ contribution and collabora-
tion, among which clinical safety science and statistical 
modeling matter experts will play ongoing critical roles in 
ensuring deliverability and objectivity. The primary purpose 
of these technical autochecks within GPVP are to send alerts 
Table 2 Proactive pharmacovigilance best practices and key processes or activities in the areas of organizational alignment, operations 
management, data management, and risk management
Organizational alignment Operations management Data management Risk management
Align operational activities across 
different functional groups and 
departments
Implement process-driven 
standard operating procedures, 
work instructions, and training 
materials
Design science-driven, site 
workflow-focused, and 
standard-based case report 
forms for post-marketing 
studies
Develop an objective, 
data-driven, team-oriented 
approach to risk monitoring 
and evaluation
Implement well-defined decision-
making models, escalation 
processes, and communication 
channels
Designate a pharmacovigilance 
operating model and business 
process owner (Debatably, 
this may be under “Risk 
management”)
Implement data mining 
techniques to bolster safety 
analytics, reporting, and 
investigation
Determine the 
pharmacovigilance workload 
and sufficiently resource the 
required effort
Incorporate continuous improve-
ment activities and standardized 
risk communication plans (Need 
buy-in from “Risk management”)
Ensure that appropriate process 
and organizational checks and 
balances are in place to limit 
bias and manage regulatory risk
Develop standard edit check 
specifications for AEs and 
adjudication process forms
Implement workflow 
management technology 
to ensure appropriate 
transparency and accessibility 
of safety information
Retain key pharmacovigilance 
personnel with cross-disciplinary 
expertise and skill sets – This will 
involve all others as well
Create dashboard to summarize 
timely awareness of safety 
risks across the portfolio and 
timely execution of safety risk 
minimization activities
Develop standard based 
metrics reports and data 
management reports
Select a vendor that best 
matches the pharmacovigilance 
operating model, business 
process and vendor/system 
selection criteria (Need 
buy-in from DM)
Examine corporate IT platform 
and have vision for a long term 
pharmacovigilance strategy
Manage and provide oversight 
to CROs recruited for portion 
or all of a clinical study
Lead integration efforts in 
building interoperability 
among CDMS, CTMS, Safety 
System, coding application
Develop risk manage-
ment action plans based on 
pre-established risk scoring 
mitigation processes
Re-organize functional groups as 
needed
May be the owner of 
coding application and data 
migration
Define and provide alert or 
signal threshold – This will 
involve others as well
Provide trainings to other 
functional groups
Abbreviations: AE, adverse event; CRO, clinical research organization; DM, data management; CDMS, clinical data management system; CTMS, clinical trial management system.Drug, Healthcare and Patient Safety 2009:1 43
IT in pharmacovigilance Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
or signals, based on pre-defined and configurable thresholds 
or ranges,13,17 to the reviewers e-mail box for assessment as 
to whether it is a true signal. It is vital that the clinical safety 
monitors be assured that any data or sets of data that may have 
a causal link to one of their drugs be detected as an alert for 
further evaluation by the clinical risk assessor.
A third unanswered question is how, exactly, the modern 
pharmacovigilance revolution will recruit the majority of 
small to mid-sized companies, pharmacies, health care 
providers, and academic communities who still use labor-
intensive traditional pharmacovigilance tools and prefer 
not to change due to various reasons, concerns, or skeptics 
on pharmacovigilance. As yet, no clear strategy has devel-
oped to assist these entities with the costs of installing, 
configuring, and integrating, and maintaining pharmaco-
vigilance systems or for convincing them that they can 
effectively function within the new practice regimes that 
the new pharmacovigilance may offer and support with 
better improved return on investment as compared to 
traditional pharmacovigilance. Additionally, convincing top 
pharmaceutical companies with well established systems and 
processes to switch to modern pharmacovigilance systems 
can be both challenging and exciting. One needs to possess 
at least the following assets to succeed: demonstration of 
system functionality, understanding business requirement, 
commitment to customer service, enhancing configurability, 
assisting with data migration and system knowledge transfer, 
offer consultation in preparation of new standard operating 
procedures or modification of existing ones, and prove cost-
saving advantages in the long-term. The most difficult seems 
to be aligning existing processes to fit in the new system. 
Often times, biopharmaceutical firms would want the system 
to have more configurable features.
Perhaps the biggest uncertainty concerning phar-
macovigilance is whether it will accomplish dramatic, 
transformational improvement in accurately and reliably 
detecting clinical safety signals among the millions of hay-
stack of voluntarily reported data. It seems reasonable that 
traditional pharmacovigilance approaches are still neces-
sitated for confirming a potential signal from an autofired 
alert, determining a potential safety risk or any action to 
be taken from a signal in pharmacovigilance. It would be 
premature to assume that modern pharmacovigilance tech-
nology will offer such critical decision-making capability. 
Even if it does, a thorough manual confirmation would 
be required at the detailed clinical data levels. Sponsor 
management is already grappling with the fact that imple-
menting pharmacovigilance corporate wide will require 
changing, quite dramatically, the work of many different 
functional groups including but not limited to: IT, clinical 
data management, safety, product performance, operations, 
CROs if applicable, clinical sites in order to create an 
operational safety framework and foster the gear switch 
to support the implementation of new technology. In the 
face of this challenge, the will to improve and prosper will 
be primary, the technology and innovation secondary, and 
patience and collaboration critical. Creating standards-
based and interoperable clinical pharmacovigilance systems 
in which corporate management and safety staff can find the 
quality improvement in signal detection and cost reduction 
essential to accomplishing corporate financial and profes-
sional goals will be necessary to widespread adoption of 
modern pharmacovigilance and to assessing its transforma-
tive potential (Figure 2).
The modern pharmacovigilance system will have the 
potential to identify and quantify adverse-event signals with 
unprecedented power and performance.18–20 Such data-mining 
capability coupled with improving standards will provide 
great benefits to optimize medications’ safety and benefit–risk 
relationships. Setting up the system to function and ensuring 
its interoperability with multiple other systems such as 
clinical data management system, coding applications, 
clinical trial management system, or product performance 
system will be a daunting task yet achievable, but making 
sure the alerts or signals it generates are epidemiologi-
cally rigorous and clinically valuable will be of paramount 
criticality. Ultimately, knowing what data mining numbers 
mean for practice, confirming potential signal or safety risk 
via further case report or case-series, and communicating that 
meaning effectively and promptly will present the biggest 
challenges of all.11 Collectively, modern pharmacovigilance 
system is a tool like all other IT ventures, and one still likely 
to be driven by humans.
Conclusion
The assessment of spontaneous reports is most effective 
when it is conducted within the defined and rigorous good 
pharmacovigilance process (GPVP) framework, a functional 
structure for both public health, health care delivery and 
corporate risk management strategy. These practices are 
designed to efficiently and effectively detect and alert the 
drug safety professional to new and potentially important 
information on drug adverse reactions. Data mining of 
adverse event databases is a tool to help with the chal-
lenging task of systematically detecting signals among 
the over 300,000 MedWatch or other similar reports Drug, Healthcare and Patient Safety 2009:1 44
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submitted annually to the FDA or similar agencies and is 
most effectively utilized with full awareness of the limita-
tions and circumstances of voluntary reporting, coding, 
database characteristics, or quality. Data-mining signals by 
themselves are not indicators of problems, but indicators 
of possible problems. Data mining is not intended to replace 
traditional pharmacovigilance techniques, but to engender 
improvement and add efficiency. Signals are generated for 
a relatively small proportion of all distinct drug–event pairs 
in the database. These signals capture a high proportion 
of the total number of drug–event pairs reported, greatly 
facilitating more focused follow-up and prioritized risk 
assessment.21 Such practices and the overall GPVP are 
supported by modern internet-based systems with powerful 
analytical engines, workflow, security, and audit trails to 
allow validated systems support for proactive drug safety 
signaling efforts. Future pharmacovigilance technology will 
have more standardization and interoperability capabilities. 
It reasons to state that pharmacovigilance has the potential 
to meet the challenges of the increasing range and potency 
of medicines (including vaccines); however, there are issues, 
concerns, challenges and risks involved in implementing 
and adopting modern pharmacovigilance solutions.
Disclosure
The author reports no conflicts of interest in this work. 
Moreover, opinions or views expressed through this article 
represent individual perspectives only.
References
  1.  WHO Collaborating Centre for International Drug Monitoring. The 
Importance of Pharmacovigilance – Safety Monitoring of Medicinal 
Products. Geneva, Switzerland: World Health Organization; 2002.
  2.  FDA Clinical Medical. Guidance for Industry – Good Pharmacovigilance 
Practices and Pharmacoepidemiologic Assessment. Rockville, MD: US 
Food and Drug Administration; 2005.
Figure 2 The interoperable clinical research and pharmacovigilance network (ICRPN). Data standard allows communications between electronic health record or medical 
record and clinical trial data, enabling clinicians and patients to share clinical information across institutional and geographic boundaries with industry sponsors. ICRPNs 
facilitate this information exchange by bringing together the groups that must participate in it to make the exchange effective. ICRPNs may also provide ongoing govern-
ance of the process of data sharing. Data exchange occurs through the information-exchange networks that provide the technical means of exchanging data between the 
records and databases maintained by clinicians, health care institutions, individual consumers, industry sponsors, and regulators.   A systematic contextual approach must 
be employed to understand and address evolving pharmacovigilance issues. 
Abbreviations: PDC, paper based data collection; IVRS, interactive voice response system; IWRS, interactive web response system;   AE, adverse event;   WHO, world health 
organization; eHR, electronic health record; eMR, electronic medical record.Drug, Healthcare and Patient Safety 2009:1
Drug, Healthcare and Patient Safety
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-healthcare-and-patient-safety-journal
Drug, Healthcare and Patient Safety is an international, peer-reviewed 
open-access journal exploring patient safety issues in the healthcare 
continuum from diagnostic and screening interventions through to treat-
ment, drug therapy and surgery. The journal is characterized by the rapid 
reporting of reviews, original research, clinical, epidemiological and 
post-marketing surveillance studies, risk management, health literacy 
and educational programs across all areas of healthcare delivery. The 
manuscript management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
45
IT in pharmacovigilance Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
  3.  Aronson JK, Ferner RE. Clarification of terminology in drug safety. 
Drug Saf. 2005;28:851–870.
  4.  Bobo R, Notte J. Safety reporting in clinical trials. Next Generation 
Pharmaceutical. Available from: http://www.ngpharma.com/pastissue/
article.asp?art=26377&issue=159. Accessed August 22, 2009.
  5.  Spink C. Pharmaceutical Clinical Development: Realising the full 
rewards of Electronic Data Capture (EDC). IBM Global Services March 
2002. Available from:http://www-935.ibm.com/services/uk/igs/pdf/
esr-pharmaceutical-clinincal-development-realising-the-full-rewards-
of-edc.pdf. Accessed October 6, 2009.
  6.  Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of 
data mining in pharmacovigilance. Drug Saf. 2005;28:981–1007.
  7.  Nelson RC, Palsulich B, Gogolak V . Good pharmacovigilance practices: 
Technology enabled. Drug Saf. 2002;25:407–414.
  8.  Lindquist M. VigiBase. The WHO Global ICSR Database System: Basic 
facts. Drug Inf J. 2008;42:409–419.
  9.  World Health Organization. WHO Programme for International Drug 
Monitoring. Available from: http://www.who-umc.org/DynPage.
aspx?id=13140&mn=1514. Accessed on August 22, 2009.
10.  Mann RD, Andrews EB (editors). Pharmacovigilance. Chichester, NH: 
John Wiley & Sons Ltd; 2002.
11.  Avorn J, Schneeweiss S. Managing drug-risk information: What to do 
with all those new numbers. N Engl J Med. 2009;361:647–649.
12.  Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms 
and computer systems to efficiently signal higher-than-expected 
combinations of drugs and events in the US FDA’s spontaneous reports 
database. Drug Saf. 2002;25:381–392.
13.  Sundström A, Hallberg P. Data mining in pharmacovigilance – detecting 
the unexpected: the role of index of suspicion of the reporter. Drug Saf. 
2009;32:419–427.
14.  Clinical Data Interchange Standards Consortium (CDISC); CDASH 
Core and Domain Teams. Clinical Data Acquisition Standards Harmo-
nization (CDASH). Austin, TX: Clinical Data Interchange Standards 
Consortium; October 2008.
15.  Buetow K. Building a 21st Century Biomedical System: the cancer 
biomedical informatics grid (caBIG®). Philadelphia, PA: Annual 
Meeting of DIA Data Conference; March 9–11, 2009.
16.  Hochberg AM, Hauben M. Time-to-signal comparison for drug safety 
data-mining algorithms vs traditional signaling criteria. Clin Pharmacol 
Ther. 2009;85:600–606.
17.  Hauben M, Aronson JK. Defining “signal” and its subtypes in pharma-
covigilance based on a systematic review of previous definitions. Drug 
Saf. 2009;32:99–110.
18.  Klein DF, O’Brien CP. Improving detection of adverse effects of 
marketed drugs. JAMA. 2007;298:333–334.
19.  Alemenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, 
Yuen N. Novel statistical tools for monitoring the safety of marketed 
drugs. Clin Pharmacol Ther. 2007;82:157–166.
20.  Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use 
of definitive anecdotal reports of adverse drug reactions as pure gold 
and high grade ore. Drug Saf. 2007;30:645–655.
21.  US Food and Drug Administration. The Sentinel Initiative: A National 
Strategy for Monitoring Medical Product Safety, May 2008. Available 
from: http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm089474.
htm. Accessed October 6, 2009.